- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000812
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide.
SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the correlation between TNF-alpha inhibition and viral burden.
A protein in the blood called tumor necrosis factor (TNF-alpha) is abnormally elevated in patients with HIV infection and may cause the body to produce more virus. In vitro studies have demonstrated that thalidomide reduces TNF-alpha levels and inhibits production of HIV. However, more information on the pharmacological and immunological aspects of thalidomide is needed.
Study Overview
Detailed Description
A protein in the blood called tumor necrosis factor (TNF-alpha) is abnormally elevated in patients with HIV infection and may cause the body to produce more virus. In vitro studies have demonstrated that thalidomide reduces TNF-alpha levels and inhibits production of HIV. However, more information on the pharmacological and immunological aspects of thalidomide is needed.
Patients are randomized to receive oral thalidomide or matching placebo (3:1) at one of three dose levels daily for 8 weeks. All 12 patients at a dose level must receive treatment for at least 2 weeks before dose escalation in subsequent patients occurs. The MTD is defined as the dose level immediately below that at which 3 or more of 9 patients receiving thalidomide experience dose-limiting toxicity. Patients are followed for a total of 16 weeks.
PER 6/20/95 AMENDMENT: Patients in cohort 1 should discontinue the previous 50 mg formulation of thalidomide once the new formulation is available. Those patients may either wash out for 4 weeks and recommence the study or discontinue the study.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80262
- University of Colorado Hospital CRS
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, ACTU
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Ctr.
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 275997215
- Unc Aids Crs
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed for occasional use (chronic use is permitted only if clinician deems that medication can be discontinued in the event of overlapping toxicity):
- CNS active agents, such as alcohol, narcotics (i.e., morphine, codeine, meperidine), barbiturates, benzodiazepines, tricyclic antidepressants, phenothiazines, sedating antihistamines, or over-the-counter sleeping aids.
Patients must have:
- HIV infection.
- CD4 count 200 - 500 cells/mm3.
- No active opportunistic infection requiring systemic therapy within the past 14 days.
- NOTE: Women must be post-menopausal or provide written documentation of surgical sterilization, and sexually active men must use a barrier method of contraception, beginning 4 weeks prior to study entry and continuing until 4 weeks following end of treatment.
PER AMENDMENT 8/2/96:
- Been on stable licensed antiretroviral treatment for 60 days prior to study entry or must not have received any antiretroviral medications for 60 days prior to study entry.
Prior Medication:
Required:
- Patients must have been on stable licensed antiretroviral treatment for 60 days prior to study entry or must not have received any antiretroviral medications for 60 days prior to study entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Malignancy requiring chemotherapy.
- Grade 2 or worse peripheral neuropathy.
- Medical condition that would interfere with evaluation of patient.
Concurrent Medication:
Excluded in all patients:
- Didanosine ( ddI ).
- Zalcitabine ( ddC ).
- Stavudine ( d4T ).
- Other immunologically active agents.
- Systemic cytotoxic chemotherapy.
Excluded in all patients unless taken only occasionally or unless medication could be stopped in the event of overlapping toxicity:
- CNS active agents, such as alcohol, narcotics (i.e., morphine, codeine, meperidine), barbiturates, benzodiazepines, tricyclic antidepressants, phenothiazines, sedating antihistamines, or over-the-counter sleeping aids.
Patients with the following prior conditions are excluded:
- History of active tuberculosis within 3 months prior to study entry.
- History of intolerance to thalidomide such as fever, rash, or neuropathy.
Prior Medication:
Excluded within 14 days prior to study entry:
- Systemic chemotherapy.
Excluded within 30 days prior to study entry:
- Topical, oral, and systemic corticosteroids.
- Pentoxifylline.
- Interferons.
- Interleukins.
- Cimetidines.
- Acetylcysteine or other glutathione depleting agents.
- Other putative immunomodulatory agents such as thymosin alpha 1, thymopentin, isoprinosine, ditiocarb sodium, ampligen, and immune globulin.
PER AMENDMENT 8/2/96:
Excluded within 60 days prior to study entry:
- Therapy with investigational antiretroviral medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Pomerantz R
- Study Chair: Teppler H
Publications and helpful links
General Publications
- Wohl D, Pomerantz R, Schmitz J, Aweeka F, Fox L, Weng D, Spritzler J, Robinson W, Holohan M, Teppler H. Thalidomide pharmacokinetics (PK) safety and effect on HIV viral load and immune parameters. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 352)
- Wohl DA, Aweeka FT, Schmitz J, Pomerantz R, Cherng DW, Spritzler J, Fox L, Simpson D, Bell D, Holohan MK, Thomas S, Robinson W, Kaplan G, Teppler H; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group 267. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002 May 1;185(9):1359-63. doi: 10.1086/340133. Epub 2002 Apr 16.
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Infections
- Communicable Diseases
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Thalidomide
Other Study ID Numbers
- ACTG 267
- 11243 (Registry Identifier: DAIDS-ES)
- 42,240
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Thalidomide
-
Henan Cancer HospitalFirst Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingEsophageal Carcinoma | Lung Cancer, Nonsmall CellChina
-
Changzhou No.2 People's HospitalUnknownEsophageal CancerChina
-
Norwegian University of Science and TechnologyThe Research Council of Norway; Nordic Myeloma Study Group, GermanyCompleted
-
Shanghai Jiao Tong University School of MedicineChanghai Hospital; Peking Union Medical College Hospital; Shanghai Zhongshan... and other collaboratorsCompletedGastrointestinal Vascular MalformationChina
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedAnkylosing SpondylitisChina
-
Valme University HospitalUniversity of SevilleUnknown
-
G.V. (Sonny) Montgomery VA Medical CenterUnknownHepatitis C Virus Infection | Infection | Herpesvirus 2, HumanUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedPrecancerous Condition | Non Neoplastic ConditionFrance
-
New York University Cancer InstituteNational Cancer Institute (NCI)CompletedSarcoma | Endometrial CancerUnited States
-
National Cancer Institute (NCI)CompletedHead and Neck CancerUnited States